Statement of Changes in Beneficial Ownership (4)
21 Octubre 2019 - 6:32PM
Edgar (US Regulatory)
|
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
Leber Laura |
2. Issuer Name and Ticker or Trading Symbol
GENOMIC HEALTH INC
[
GHDX
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Chief Communication Officer
|
|
(Last)
(First)
(Middle)
301 PENOBSCOT DR. |
3. Date of Earliest Transaction
(MM/DD/YYYY)
10/17/2019
|
|
(Street)
REDWOOD CITY, CA 94063
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
|
Common Stock
|
3/11/2019
|
|
G
|
V
|
275
|
D
|
$0.00
|
13420 (1)
|
D
|
|
|
Common Stock (2)
|
10/17/2019
|
|
M
|
|
13183
|
A
|
$22.98
|
26919 (1)
|
D
|
|
|
Common Stock (2)
|
10/17/2019
|
|
S
|
|
13183
|
D
|
$70.942 (3)(4)
|
13736 (1)
|
D
|
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3)
|
2. Conversion or Exercise Price of Derivative Security
|
3. Trans. Date
|
3A. Deemed Execution Date, if any
|
4. Trans. Code
(Instr. 8)
|
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
6. Date Exercisable and Expiration Date
|
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
|
8. Price of Derivative Security
(Instr. 5)
|
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)
|
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)
|
11. Nature of Indirect Beneficial Ownership (Instr. 4)
|
|
Code
|
V
|
(A)
|
(D)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
|
Employee Stock Option (right to buy)
|
$22.98
|
10/17/2019
|
|
M
|
|
|
13183
|
(5)
|
1/27/2021
|
Common Stock
|
13183
|
$0.00
|
0
|
D
|
|
|
Explanation of Responses:
|
| (1)
|
Includes an aggregate of 9,384 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
|
| (2)
|
These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on November 14, 2018.
|
| (3)
|
Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
|
| (4)
|
Represents weighted average sale price. Actual sale prices ranged from $70.71 to $71.135.
|
| (5)
|
The option became exercisable as to 25% of the shares on January 27, 2012, and became exercisable as to 1/48th of the shares each full month thereafter.
|
Reporting Owners
|
|
Reporting Owner Name / Address
|
Relationships
|
|
Director
|
10% Owner
|
Officer
|
Other
|
Leber Laura
301 PENOBSCOT DR.
REDWOOD CITY, CA 94063
|
|
|
Chief Communication Officer
|
|
Signatures
|
|
/s/ Jason W. Radford, Attorney-in-fact
|
|
10/21/2019
|
|
**Signature of Reporting Person
|
Date
|
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
|
*
|
If the form is filed by more than one reporting person, see Instruction 4(b)(v).
|
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
|
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
Genomic Health (NASDAQ:GHDX)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024
Genomic Health (NASDAQ:GHDX)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024
Real-Time news about Genomic Health Inc (NASDAQ): 0 recent articles
Más de Genomic Health Inc Artículos de Noticias
Parece que no se ha autenticado. Haga click al botón de abajo para iniciar la sesión y ver los símbolos recientemente consultados.
| Precios en Tiempo Real | Nivel 2 |
|---|
| | |
|---|
*Durante 3 años $1.035.00 solo $414.00